Compare Repligen Corporation Common Stock (RGEN) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs UnitedHealth Group Inc — how do they compare? Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B), while UnitedHealth Group Inc trades at $396.5 (market cap $339.08B). The key difference: UnitedHealth Group Inc is far larger — about 30.4× Repligen Corporation Common Stock's market cap, and UnitedHealth Group Inc pays a 2.46% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| RGEN | UNH | |
|---|---|---|
Market Cap | $11.14B | $339.08B |
Volume | 1,259,263 | 12,648,635 |
Sector | Health | Health |
52-Week High | $194.57 | $436.35 |
52-Week Low | $102.87 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $11.02B | $380.94B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
UnitedHealth Group (UNH) trades at $378.52, down 0.21% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats in recent quarters, including Q3 2026 EPS of $4.69 beating expectations of $4.14. Revenue growth remains solid at $447.57B for 2025, though net margins have compressed to 3.14%. Recent developments include strategic moves with TPG for WellMed operations and continued AI investments in Optum Insight.
UNH presents a compelling investment case with 82.7% analyst buy ratings and a $470.11 consensus price target representing 24% upside. The company's Medicare Advantage strength and Optum improvements support growth, though regulatory scrutiny and medical cost pressures remain key risks. Strong institutional ownership and Michael Burry's recent call option position signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
